Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Bullboard Posts
Post by 1hot-techwomanon Mar 07, 2018 10:27am
103 Views
Post# 27675025

Sad to see ABCN like this with so much potential :( ???

Sad to see ABCN like this with so much potential :( ???ABcann Global Provides Business Update Tuesday, March 06, 2018, 7:00 AM ET ABcann Global Provides Business Update NAPANEE, Ontario, March 06, 2018 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSXV:ABCN) ("ABcann" or the "Company") is pleased to provide the following business update. "Over the past five months we have enhanced our leadership team, strengthened our balance sheet, improved operational effectiveness and executed a strategic acquisition. Last week, after completing an extensive strategic review of our operations and growth plans, our board of directors approved our 2018 Business Plan, and the ABcann team is now sharply focused on execution," stated Barry Fishman, Chief Executive Officer. With the closing of our recent oversubscribed financing of $75 million, the Company is well-positioned with over $135 million in cash to accelerate the growth of our business. A disciplined capital allocation process is in place, with the following four priorities: 1. Expanding to 500,000 square feet to produce over 30,000 kilograms of capacity 2. Focusing on branding and product innovation in the medical and adult-use sectors 3. Expanding our proven Harvest Medicine platform to multiple new locations in 2018; and 4. Developing strategic partnerships in the industry to broaden our reach and scale ABcann is widely recognized as a producer of premium cannabis -- grown using proprietary advanced techniques tailored to optimize quality and consistency. High-tech growing is our current differentiator. Our technology allows us to precisely control environmental variables to maximize yield and produce pharmaceutical-grade cannabis. "In mid-2018 we are excited to roll-out a complete corporate and product line rebrand to better match our strategic vision and desired product positioning in both the medical and adult-use markets. More details will follow in an upcoming release," said Mr. Fishman." The Company continues to pursue international opportunities and aims to obtain a distribution license for Germany after GMP certification of its Vanluven facility and required stability testing is completed. The Company is expecting to begin exporting cannabis to Australia mid-year, and to Germany close to year-end, and continues to assess opportunities in other international markets.
Bullboard Posts